Hildy Dillon

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma”.

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

New England Journal of Medicine(2024)10.1056/nejmoa2405888

N/A

3.4DataRank · unranked

211 citations

Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens +42 more

SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and validate a prospective frailty tool

Journal of Geriatric Oncology(2021)10.1016/j.jgo.2021.10.003

N/A

0.736DataRank · unranked

24 citations

Hongli Li, Anne Beaven, Paolo F. Caimi, Leandro Cerchietti, Ash A. Alizadeh +9 more

127 | HEALTH‐RELATED QUALITY OF LIFE (HRQoL) ENDPOINTS OF THE PHASE III INTERGROUP S1826 ADVANCED‐STAGE, CLASSIC HODGKIN LYMPHOMA (cHL) TRIAL

Hematological Oncology(2025)10.1002/hon.70093_127

N/A

0DataRank · unranked

1 citations

H. Li, Alex F. Herrera, Kelly Davison, Sharon M. Castellino, Hildy Dillon +11 more